Treatment of Bronchial Asthma With Borage and Echium Seed Oils
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00806442|
Recruitment Status : Completed
First Posted : December 10, 2008
Results First Posted : July 3, 2017
Last Update Posted : July 3, 2017
|Condition or disease||Intervention/treatment||Phase|
|Bronchial Asthma||Drug: Borage Seed Oil and Echium Seed Oil Dietary Supplement: Corn Oil||Phase 1 Phase 2|
Leukotrienes are important in the pathogenesis of inflammation, and leukotriene modifying drugs are now an established treatment for bronchial asthma and rhinitis. Drugs that inhibit the biosynthesis of leukotrienes are likely to be more effective than the currently available drugs that antagonize a single leukotriene receptor. Dietary supplementation with gamma linolenic acid (GLA) in borage seed oil provides effective inhibition of leukotriene generation but also increases circulating free arachidonic acid (AA), which has pro-inflammatory potential. The n-3 fatty acid, eicosapentaenoic acid (EPA), prevented the conversion of GLA to AA. However, EPA is extracted from fish oil, is not well-tolerated due to its taste, and at higher doses appeared to blunt the inhibition of leukotriene biosynthesis by GLA. Stearidonic acid (SDA) is a precursor of EPA that is extracted from Echium plantagineum; it is converted to EPA in humans and it does not have the organoleptic properties of EPA.
We recently completed a dose-ranging study in which we determined the dose of SDA that is sufficient to inhibit the rise in circulating levels of arachidonic acid while maintaining effective inhibition of leukotriene generation.
The goal of the present study is to test the efficacy of dietary supplementation with GLA and SDA (provided in borage seed oil and echium seed oil) in treating bronchial asthma.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||43 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||Treatment of Bronchial Asthma With Borage and Echium Seed Oils|
|Study Start Date :||December 2008|
|Actual Primary Completion Date :||April 2012|
|Actual Study Completion Date :||August 2012|
Experimental: 1: Borage Seed Oil and Echium Seed Oil
Borage/Echium plant seed oils: 2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
Drug: Borage Seed Oil and Echium Seed Oil
2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
Placebo Comparator: 2: Placebo Comparator
Placebo comparator: 9 g/day corn oil
Dietary Supplement: Corn Oil
9 g/day of corn oil
- Forced Expiratory Volume in 1 Second (FEV1) [ Time Frame: 6 weeks ]Forced expiratory volume in 1 second (FEV1) in plant seed oil vs. placebo
- Positive FEV1 Percent Predicted Change Among C Allele Carriers and A Homozygotes [ Time Frame: 6 weeks on each treatment assignment ]Number of participants with positive change in FEV1 % predicted (>0%) among C allele carriers and A homozygotes in each arm
- Peak Flow Rate (PEFR) [ Time Frame: 6 weeks ]Morning Peak Flow Rate in plant seed oil vs. placebo
- Frequency of Rescue Use of Short Acting Beta-2 Agonists [ Time Frame: 6 weeks ]Average number of puffs of albuterol daily in plant seed oil vs. placebo
- Day-time Symptoms of Bronchial Asthma [ Time Frame: 6 weeks ]
Day-time symptom scores in plant seed oil vs. placebo. 0 = Absent: No symptoms
- = Mild: Symptom did not interfere with normal daily activity or sleep
- = Moderate: Symptom was sufficient to interfere with normal daily activity or sleep
- = Severe: Symptom was so severe as to prevent normal daily activity or sleep
These numbers were used for 1. Shortness of breath 2. Chest tightness 3. Wheezing 4. Cough 5. Phlegm/Mucus.
The total score is the sum of the 5 item scores, for a range of 0-15. A higher score represents more severe symptoms. Each participant's score is the average of varying numbers of diary cards. The treatment phase visits at 6 weeks consisted of 3 weeks of diary cards with a +/- 5 day window. The baseline visits had 2 weeks of diary cards with a +/- 5 day window. The treatment phase measures are adjusted for the baseline measures.
- Night-time Wakenings [ Time Frame: 6 weeks ]Average number of night-time wakenings in plant seed oil vs. placebo
- Urinary Leukotriene Levels [ Time Frame: 6 weeks ]Urinary leukotriene levels in plant seed oil vs. placebo
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00806442
|United States, Massachusetts|
|Asthma Research Center, Brigham and Women's Hospital|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Elliot Israel, MD||Brigham and Women's Hospital|